Early CAR-T therapy shows promising results in high-risk multiple myeloma patients

A study evaluated the use of early chimeric antigen receptor T-cell therapy (CAR-T) in high-risk multiple myeloma patients. The CARMA-3 trial administered the CAR-T therapy, iDECeL, to patients with two to four prior lines of therapy. Results showed a response rate of 86%, with even favorable outcomes in patients who previously received BCMA-directed therapy. The study highlights the potential for CAR-T therapy to overcome high-risk disease and provides a targeted treatment option with GPRC5D as the antigen. While BCMA-directed therapies remain effective, exploring new targets like GPRC5D expands treatment possibilities.